申请人:Claremon David A.
公开号:US20120232050A1
公开(公告)日:2012-09-13
This invention relates to novel compounds of the Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (III). (III-A). (IIII-B). (III-C). (III-D), (III-E) (IV), (IV-A), (IV-B). (IV-C), (IV-D). (V), (V-A), (V-B), (V-C), (V-D), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
本发明涉及式(I),(II),(II-A),(II-B),(II-C),(II-D),(III),(III-A),(IIII-B),(III-C),(III-D),(III-E),(IV),(IV-A),(IV-B),(IV-C),(IV-D),(V),(V-A),(V-B),(V-C),(V-D)的新化合物,其药学上可接受的盐以及其制备的药物组合物,适用于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病。本发明还涉及新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法的使用。